Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PBPV in Adults 50+
NCT05622942Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Protein Based Pneumococcal Vaccine in pneumococcal infection (2 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Incidence of adverse reactions 0~7 days after vaccination, Incidence of adverse reactions 0~30 days after vaccination and 1 more. Started Mar 2023; status: completed.
02
Drugs
Protein Based Pneumococcal Vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05622942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622942.